摘要
受体络氨酸激酶c-Met/HGF途径的异常活化与细胞增殖、入侵、代谢,及许多类型肿瘤包括上消化道肿瘤的不良预后有关。c-Met和多信号通路包括肿瘤发生的特性和侵略性表型的相互作用已经获得了大量关注,表明其在癌症治疗中扮演着富有吸引力的靶点角色。最近几年,在具有潜在的临床应用的、有效的c-Met抑制剂的发展上已经做出了很大的努力,其中一个抑制剂,克唑替尼(双重c-Met/ALK抑制剂)最近被批准应用于具有ALK重排的肺癌治疗。然而有几个重要的问题关于克唑替尼潜在的抗癌作用及其在不同肿瘤类型包括上消化道癌症中发挥的可能的治疗作用的分子机制仍然有待回答。这篇综述的目的是为c-Met/HGF通路在癌症方面的关键作用及c-Met抑制剂的临床前或临床研究提供一个综述。越来越多的证据证明了c-Met抑制剂在其他恶性肿瘤上具有治疗潜力,例如胃癌和胰腺癌。但是, c-Met抑制剂活性的决定因素的识别仍然需要进一步的研究,通过分析影响c-Met和平行的癌症前通路的遗传和环境改变;导致抗c-Met药物发生的机制;被选择的患者可能从治疗中获益。这些研究在改善未来的c-Met靶向疗法在上消化道癌症治疗中的抗癌策略的选择性和有效性上是十分必要的。
关键词: c-Met/HGF通路,c-Met抑制剂,靶向药物耐受,上消化道肿瘤
Current Drug Targets
Title:Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Volume: 15 Issue: 14
Author(s): Sharareh Gholamin, Hamid Fiuji, Mina Maftouh, Reza Mirhafez, Fatemeh Homaei Shandiz and Amir Avan
Affiliation:
关键词: c-Met/HGF通路,c-Met抑制剂,靶向药物耐受,上消化道肿瘤
摘要: Aberrant activation of receptor-tyrosine kinase c-Met/HGF pathway is shown to be associated with cell proliferation, invasion, metastasis and poor-prognosis in several tumor types, including upper gastrointestinal-malignancies. The interaction of c-Met with multiple signalling-pathways involved in tumorigenic-properties and invasive-phenotype has gained substantial attention, suggesting its role as an intriguing-target for cancer-therapy. In recent years, there have been considerable efforts in the development of effective c-Met inhibitors with potential clinical-applications and one of them, crizotinib (dual c-Met/ALK inhibitor), has recently been approved for lung-cancers with ALKrearrangement. However several important questions remain to be answered on the molecular mechanisms underlying the antitumor effects of crizotinib, as well as on its possible role in the treatment of different tumor types, including uppergastrointestinal- cancers. The aim of this review is to give an overview on critical role of the c-Met/HGF pathway in cancer, and the preclinical/clinical studies on c-Met inhibitors. There are accumulating evidences on therapeutic potential of c-Met inhibitors for the treatment of other malignancies, such as gastric and pancreatic cancers. However, further investigations are needed to identify determinants of the activity of c-Met inhibitors, through the analysis of genetic/ environmental alterations affecting c-Met and parallel pro-cancer pathways; mechanisms result in developing resistance to anti-c-Met agents; and selection of patients that might benefit from therapy. These studies will be essential to improve the selectivity/efficacy of future anticancer strategies of c-Met targeted-therapies in the treatment of upper gastrointestinal- cancers.
Export Options
About this article
Cite this article as:
Sharareh Gholamin, Hamid Fiuji, Mina Maftouh, Reza Mirhafez, Fatemeh Homaei Shandiz and Amir Avan , Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/1389450115666141107105456
DOI https://dx.doi.org/10.2174/1389450115666141107105456 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Bestatin as an Experimental Tool in Mammals
Current Drug Metabolism Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Novel Nanocolloidal Carriers for Noninvasive Vaccine Delivery
Current Drug Therapy The Pathogenic Role of Intestinal Flora in IBD and Colon Cancer
Current Drug Targets Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Drug Delivery & Formulation C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Recent Aspects of Osmotic Pump Systems: Functionalization, Clinical use and Advanced Imaging Technology
Current Drug Metabolism Probiotic Properties of a Spaceflight-induced Mutant Lactobacillus Plant- arum SS18-50 in Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Nimesulide is a Selective COX-2 Inhibitory, Atypical Non-Steroidal Anti-Inflammatory Drug
Current Medicinal Chemistry Medicinal Chemistry and Anti-Inflammatory Activity of Nitric Oxide-Releasing NSAI Drugs
Mini-Reviews in Medicinal Chemistry MicroRNAs as Therapeutic Targets for Anticancer Drugs in Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Determination of the Antiproliferative Activity of New Theobromine Derivatives and Evaluation of Their In Vitro Hepatotoxic Effects
Anti-Cancer Agents in Medicinal Chemistry